bullish
Unlock 1 Ill-Effects: Boon for the Consumer Discretionary?
301 Views19 Jun 2020 13:36
The previous insight related to our Covid-19 coverage, Covid-19: Dull Economic Package, Lock-Down 4.0 Consequences highlighted that the economy is...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
- Biocon: Covid-19 Respite Uncertain29 Jul 2020
- Jubilant Pharma: Good Drugs, Fully-Valued Bonds26 Jun 2020
- Glenmark Pharma: Approval for Covid-19 Oral Drug21 Jun 2020
- Unlock 1 Ill-Effects: Boon for the Consumer Discretionary?19 Jun 2020
- Covid-19: Dull Economic Package, Lock-Down 4.0 Consequences23 May 2020
- Covid 19: Instead of Panacea Lockdown Turns Albatross Around Neck30 Apr 2020
x